Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription 02.11.2026 1 Am J Surg 5 Ann Oncol 4 Ann Surg Oncol 5 Anticancer Res 5 BMC Cancer 5 Breast Cancer 5 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 6 Breast Cancer Res Treat 1 Cancer Cell 1 Cancer Res 1 Eur J Cancer 4 Eur J Surg Oncol 2 J Clin Oncol 7 J Natl Cancer Inst 3 JAMA 1 Lancet 2 Lancet Oncol 1 N Engl J Med 1 Oncol Rep 1 PLoS Genet 1 PLoS Med 8 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Radiol Imaging Cancer

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. SCHUPP E, Gokun Y, Chen JC, Elsaid MI, et al
   Association between postoperative complications and recurrence-free survival in patients with hormone receptor-positive, HER2 negative breast cancer.
   Am J Surg. 2026;263:117290.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. CUNNINGHAM N, Swift C, Cutts RJ, Thomas K, et al
   Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study.
   Ann Oncol. 2026 Oct 27:S0923-7534(26)08644-8. doi: 10.1016/j.annonc.2026.10.1292
   PubMed         Abstract available
   
   
3. XU B, Yin Y, Fan Y, Ouyang Q, et al
   Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.
   Ann Oncol. 2026 Dec 31:S0923-7534(26)06880-8. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   
4. KALINSKY K, Wander SA, Hamilton E, Graff SL, et al
   Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy.
   Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283
   PubMed         Abstract available
   
   
5. GIORDANO A, Xu B, Yoshinami T, Huang CS, et al
   Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
   Ann Oncol. 2026 Oct 24:S0923-7534(26)08074-9. doi: 10.1016/j.annonc.2026.10.1282
   PubMed         Abstract available
   
   
6. RUGO HS, Kok M, Goncalves A, Loirat D, et al
   Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1?Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.
   Ann Oncol. 2026 Oct 24:S0923-7534(26)08077-4. doi: 10.1016/j.annonc.2026.10.1285
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. SULLIVAN S, Lizarraga IM
   ASO Author Reflections: Necessary Complexity or Avoidable Delay? Increasing Time to Breast Cancer Surgery and the 60-day Measure.
   Ann Surg Oncol. 2026 Oct 28. doi: 10.1245/s10434-026-20819.
   PubMed        
   
   
8. GASS JS, Pesek S, Czerniecki B, Ryan J, et al
   ASO Visual Abstract: An International Randomized Prospective Trial Comparing a Supine MRI-based Guidance System, The Breast Cancer Locator(TM) , to Wire Localization for Breast-Conserving Surgery for Nonpalpable Breast Cancer.
   Ann Surg Oncol. 2026 Oct 27. doi: 10.1245/s10434-026-20758.
   PubMed        
   
   
9. ARIMA J, Chida K, Wu R, Shima T, et al
   ASO Author Reflections: Androgen Receptor as a Potential Biomarker and Therapeutic Target for Immunotherapy in ER-positive/HER2-negative Breast Cancer.
   Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20801.
   PubMed        
   
   
10. ELSAEDY EA, AlRammah T, Kawashima K, Ebos JML, et al
    ASO Visual Abstract: High Expression of Aurora Kinase A (AURKA) Is Associated with Aggressive Tumor Biology and Therapeutic Response in ER+/HER2- Breast Cancer.
    Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20676.
    PubMed        
    
    

    
    Anticancer Res

11. PARK SC, Ho JS, Won RH, Kwon YB, et al
    Predictors of Pathologic Complete Response Following Neoadjuvant Chemotherapy in Invasive Breast Cancer With Microcalcifications.
    Anticancer Res. 2026;46:6275-6285.
    PubMed         Abstract available
    
    
12. IMAI Y, Mimura Y, Iida M, Ito N, et al
    Baseline Serum Albumin Is Associated With Severe Adverse Events During Trastuzumab Deruxtecan Treatment in Metastatic Breast Cancer.
    Anticancer Res. 2026;46:6183-6192.
    PubMed         Abstract available
    
    
13. KAWAMURA Y, Mori K, Takeuchi F, Kawano J, et al
    Tumor Immune Microenvironment and VAF-inferred BRCA1/2 Loss of Heterozygosity in Japanese Patients With Germline BRCA1/2-mutated Breast Cancer.
    Anticancer Res. 2026;46:6099-6111.
    PubMed         Abstract available
    
    
14. GUO Y, Li Y, Xiao X, Song Z, et al
    Temporal Dynamics and Black-White Patient Differences in Contralateral Invasive Breast Cancer Risk Following DCIS and IDC: A Time-Varying Competing-Risks Analysis.
    Anticancer Res. 2026;46:6437-6450.
    PubMed         Abstract available
    
    
15. OSAWA Y, Kumazaki A, Imanaka K, Ohmoto Y, et al
    Breast Cancer Side Population Versus CD44(+)/CD24(-) Cells: Functional and Tumorigenic Differences.
    Anticancer Res. 2026;46:6041-6050.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. PRADO V, Esperanca G, Nahas GP, Maya BG, et al
    Metabolic health at breast cancer diagnosis and two-year survival: a prospective cohort study in a public healthcare setting.
    BMC Cancer. 2026;26:1309.
    PubMed         Abstract available
    
    
17. ZHANG YJ, Liang ZM, Huang XY, Yu YJ, et al
    Pre-treatment prediction of response to neoadjuvant chemotherapy in breast cancer patients using a nomogram based on findings from cone-beam breast computed tomography.
    BMC Cancer. 2026;26:1318.
    PubMed         Abstract available
    
    
18. CONCATO-LOPES VM, Cruz EMS, de Lima LVA, Goncalves-Lens MD, et al
    The biphenyl dimeric compound 3,3',5,5'-tetramethoxybiphenyl-4,4'-diol disrupts redox homeostasis and mitochondrial function to inhibit growth and induce apoptosis in breast cancer monolayers and 3D tumor spheroids.
    BMC Cancer. 2026;26:1306.
    PubMed         Abstract available
    
    
19. ZHANG S, Xu L, Peng W
    A novel Hemoglobin-Albumin-Lymphocyte-Platelet (HALP)-based prognostic model to predict the progression of premenopausal breast cancer: a retrospective cohort study.
    BMC Cancer. 2026;26:1294.
    PubMed         Abstract available
    
    
20. WRIGHT FM, Vasileva-Slaveva M, Yordanov A, Ivanov I, et al
    Characterisation of a novel p53 mutation (p53(N263Tfs*7)) associated with li-fraumeni syndrome.
    BMC Cancer. 2026;26:1297.
    PubMed         Abstract available
    
    

    
    Breast Cancer

21. NAHSHON C, Fahoum L, Hadar D, Cohen H, et al
    Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant.
    Breast Cancer. 2026;33:1271-1279.
    PubMed         Abstract available
    
    
22. USHIYAMA Y, Ueki Y, Horimoto Y, Yoshino M, et al
    Prognostic performance of the Japanese Breast Cancer Society pathological response classification after neoadjuvant chemotherapy.
    Breast Cancer. 2026 Oct 27. doi: 10.1007/s12282-026-01933.
    PubMed         Abstract available
    
    
23. ZHAI M, Wang P, Ou Y
    Molecular mechanisms and targeted therapeutic strategies of TIGAR in regulating energy metabolism to promote tumor proliferation in breast cancer.
    Breast Cancer. 2026 Oct 25. doi: 10.1007/s12282-026-01929.
    PubMed         Abstract available
    
    
24. FEARN N, Kilbreath S, Dylke E, Wang W, et al
    Comparison of four breast lymphoedema patient reported outcome measures in women following breast conserving surgery and radiotherapy: examination of frequencies of symptoms and measurement properties.
    Breast Cancer. 2026;33:1406-1418.
    PubMed         Abstract available
    
    
25. YILDIRIM SF, Demir P, Kosku H, Yalcin B, et al
    Clinical impact of ENIGMA-based variant reclassification on genotype-phenotype analyses in BRCA1- and BRCA2-associated hereditary breast and ovarian cancer.
    Breast Cancer. 2026;33:1329-1339.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

26. ALI EI, Abusail Mustafa S, Elzein HO, Andarawi MO, et al
    Clinicopathological Profile, Treatment Patterns and Documented Clinical Outcomes of Women with Breast Cancer at Shendi Hospital, Sudan: A Retrospective, Single-Center, Hospital-Based Cross-Sectional Study.
    Breast Cancer (Dove Med Press). 2026;18:650507.
    PubMed         Abstract available
    
    
27. LI M, Shi J
    Predictive Value of Combined Ultrasound Viscoelasticity Imaging, CEUS, AAPR, and PLR for Assessing Neoadjuvant Chemotherapy Efficacy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:636920.
    PubMed         Abstract available
    
    
28. RAHMAN I, Henidi H, Alshibli A, Bin-Murdhi NS, et al
    Glucose-Dependent Cytotoxic Responses in Triple-Negative Breast Cancer: Experimental and Transcriptomic Evidence of Metabolic Context and p38 MAPK-Associated Modulation.
    Breast Cancer (Dove Med Press). 2026;18:623153.
    PubMed         Abstract available
    
    
29. MUGLU H, Erol VB, Ozcelik H, Sunger E, et al
    Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis.
    Breast Cancer (Dove Med Press). 2026;18:647399.
    PubMed         Abstract available
    
    
30. LIU Y, Liu Y, Wang H, Xiao Z, et al
    Development and External Validation of an M2 Macrophage-Related Prognostic Signature in Breast Cancer Using Multi-Omics Data and Machine Learning.
    Breast Cancer (Dove Med Press). 2026;18:636369.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

31. CHAN M, Lilge L, Walter J, Tehranifar P, et al
    Use of hair relaxers and hair dyes during pregnancy and breast tissue composition in mothers and adolescent daughters.
    Breast Cancer Res. 2026;28:183.
    PubMed         Abstract available
    
    
32. ABUBAKAR M, Sayed S, Koka H, Lawrence S, et al
    Spatially dissecting drivers of inter- and intra-tumoral heterogeneity in Kenyan breast cancer.
    Breast Cancer Res. 2026;28:182.
    PubMed         Abstract available
    
    
33. ROBINSON D, Kim H, Selico-Dunn A, Elkins E, et al
    CK2 targeting potentiates antineoplastic effects of dual HER2/EGFR inhibitor lapatinib and attenuates growth factor-induced epithelial-mesenchymal transition.
    Breast Cancer Res. 2026;28:184.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

34. MAHAJAN A, Panda SS, Moharana L, Chandrakanth MV, et al
    Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA((R))) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.
    Breast Cancer Res Treat. 2026;220:20.
    PubMed         Abstract available
    
    
35. SARATHCHANDRA S, Nyqvist-Streng J, Sahlberg E, Einbeigi Z, et al
    Sociodemographic and clinicopathologic features associated with rapid relapse in triple-negative breast cancer: a Swedish nationwide registry-based study.
    Breast Cancer Res Treat. 2026;220:19.
    PubMed         Abstract available
    
    
36. CRONIN KM, Tiersten A
    GLP-1 receptor agonist-associated weight loss in breast cancer patients receiving concurrent endocrine therapy: a retrospective cohort analysis.
    Breast Cancer Res Treat. 2026;220:17.
    PubMed         Abstract available
    
    
37. DOLCE EM, Darga EP, Henderson NC, Thomas DG, et al
    Circulating tumor cells in lobular versus ductal metastatic breast cancer.
    Breast Cancer Res Treat. 2026;220:15.
    PubMed         Abstract available
    
    
38. SMITH CE, Rami A, Li T, Tayob N, et al
    Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice.
    Breast Cancer Res Treat. 2026;220:16.
    PubMed         Abstract available
    
    
39. DELGADO CASANOVA LB, Dhamne S, Resetkova E, Guirguis MS, et al
    Risk of malignancy after diagnosis of radial sclerosing lesion with associated atypia.
    Breast Cancer Res Treat. 2026;220:18.
    PubMed         Abstract available
    
    

    
    Cancer Cell

40. CONFORTI F, Nekljudova V, Holtschmidt J, Sala I, et al
    CPS + EG and Neo-Bioscore predict individual outcomes but not trial results after neoadjuvant therapy for early breast cancer.
    Cancer Cell. 2026 Oct 27:S1535-6108(26)00437-X. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    

    
    Cancer Res

41. DEWITT JT, Jimenez-Tovar D, Oropeza E, Tiftik Karabay E, et al
    Patient Sociodemographic Factors Impact the Breast Cancer Microenvironment.
    Cancer Res. 2026 Oct 26. doi: 10.1158/0008-5472.CAN-25-5500.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

42. CALTAVITURO A, Giordano A, De Angelis C, Buonaiuto R, et al
    Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR?+?/HER2- metastatic breast cancer.
    Eur J Cancer. 2026;249:117794.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

43. LEE J, Bae SJ, Yoon CI, Do SI, et al
    A simple three-variable triage rule using PR Allred score, standardized digital Ki-67, and histologic grade to identify an Oncotype DX recurrence score of 25 or less in HR+/HER2- early breast cancer.
    Eur J Surg Oncol. 2026;53:112329.
    PubMed         Abstract available
    
    
44. DEO SVS, Wiley S, Dietz J, Karakatsanis A, et al
    Preoperative core competencies in oncoplastic breast surgery: Recommendations from the international breastics working group.
    Eur J Surg Oncol. 2026;52:112079.
    PubMed         Abstract available
    
    
45. KEATING N, Harding T, Rothwell J, Evoy D, et al
    Margin positivity and re-excision after breast-conserving surgery following neoadjuvant chemotherapy: A systematic review and meta-analysis.
    Eur J Surg Oncol. 2026;52:112128.
    PubMed         Abstract available
    
    
46. LUCOCQ J, Gallagher K, Catanuto G, Masannat Y, et al
    A geometric framework for volumetric decision-making in oncoplastic breast-conserving surgery: A mixed methods development study.
    Eur J Surg Oncol. 2026;52:112136.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

47. TUNG N, Zhao F, DeMichele A, Prat A, et al
    Erratum: Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.
    J Clin Oncol. 2026 Oct 30:JCO2602664. doi: 10.1200/JCO-26-02664.
    PubMed        
    
    
48. ABDOU Y, Carey LA
    From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2026 Oct 30:JCO2601976. doi: 10.1200/JCO-26-01976.
    PubMed        
    
    

    
    J Natl Cancer Inst

49. MARGOLIS S, Kalbasi TR, Zektser Y, Niknafs A, et al
    Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis.
    J Natl Cancer Inst. 2026 Oct 23:djag399. doi: 10.1093.
    PubMed         Abstract available
    
    
50. ERGUN Y
    RE: Endocrine Therapy in Early-stage Estrogen Receptor-Low Breast Cancer: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2026 Oct 23:djag361. doi: 10.1093.
    PubMed        
    
    
51. BERGSTROM CP, Luo I, Bean GR, Kotler E, et al
    A clinical model incorporating early lymphocyte dynamics in HER2-positive breast cancer.
    J Natl Cancer Inst. 2026 Oct 24:djag400. doi: 10.1093.
    PubMed         Abstract available
    
    
52. ZHU L, Liu L
    RE: Endocrine therapy in early-stage estrogen receptor-low breast cancer: a systematic review and meta-analysis.
    J Natl Cancer Inst. 2026 Oct 23:djag362. doi: 10.1093.
    PubMed        
    
    
53. BLINDER VS, Sampathkumar Y, Patil S, Eberle CE, et al
    Employment after curative breast cancer treatment: the breast cancer and the workforce cohort study.
    J Natl Cancer Inst. 2026 Oct 23:djag384. doi: 10.1093.
    PubMed         Abstract available
    
    
54. ETESSAMI JD, Curigliano G, Valenza C
    Tailoring adjuvant endocrine therapy in patients with estrogen receptor-low breast cancer.
    J Natl Cancer Inst. 2026 Oct 26:djag354. doi: 10.1093.
    PubMed        
    
    
55. HE M, Rimm DL
    The right drug, the wrong assay: TROP2-ADC assessment in breast cancer.
    J Natl Cancer Inst. 2026 Oct 27:djag275. doi: 10.1093.
    PubMed        
    
    

    
    JAMA

56. MOSELE MF, Andre F
    Trastuzumab Rezetecan in EBBR2-Low Metastatic Breast Cancer: One More ADC or a New Opportunity?
    JAMA. 2026 Oct 23. doi: 10.1001/jama.2026.22295.
    PubMed        
    
    
57. 
    Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: Research Summary.
    JAMA. 2026 Oct 23:e2621700. doi: 10.1001/jama.2026.21700.
    PubMed        
    
    
58. FAN Y, Liu Y, Wang Y, Ouyang Q, et al
    Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.
    JAMA. 2026 Oct 23:e2621372. doi: 10.1001/jama.2026.21372.
    PubMed         Abstract available
    
    

    
    Lancet

59. LAN B, Shi Y, Shao X, Wu F, et al
    Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
    Lancet. 2026 Oct 26:S0140-6736(26)02096-9. doi: 10.1016/S0140-6736(26)02096.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

60. WILKINSON E
    There is beauty after breast cancer.
    Lancet Oncol. 2026;27:1365-1366.
    PubMed        
    
    
61. GOURD E
    WHO releases framework for expanding access to early breast cancer care.
    Lancet Oncol. 2026 Oct 29:S1470-2045(26)00591.
    PubMed        
    
    

    
    N Engl J Med

62. WANG J, Li H, Xu F, Wu T, et al
    Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer.
    N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2610345.
    PubMed         Abstract available
    
    

    
    Oncol Rep

63. YU X, Ren M, Yao L
    Advances in resistance mechanisms and counterstrategies for antibody?drug conjugates in HER2?low and HER2?ultralow breast cancer (Review).
    Oncol Rep. 2026;56:208.
    PubMed         Abstract available
    
    

    
    PLoS Genet

64. MUSICK M, Ufondu CA, Rowland CE, Brown ME, et al
    CDH1 loss remodels gene expression and lineage identity in human mammary epithelial cells.
    PLoS Genet. 2026;22:e1012351.
    PubMed         Abstract available
    
    

    
    PLoS Med

65. STAROWICZ K
    Breast cancer treatment: When less is more.
    PLoS Med. 2026;23:e1005284.
    PubMed         Abstract available
    
    

    
    PLoS One

66. JUTAGIR DR, Espinosa A, Lopez M, Claros M, et al
    Identifying barriers to immunotherapy access for triple-negative breast cancer: A qualitative analysis of interviews with medical oncologists.
    PLoS One. 2026;21:e0361021.
    PubMed         Abstract available
    
    
67. CASTILLO H, Sebio-Garcia R, Martinez-Palli G, Siso M, et al
    Multimodal lifestyle intervention during neoadjuvant chemotherapy in patients with early breast cancer as a strategy to improve treatment response: Protocol of the DIANA randomized clinical trial.
    PLoS One. 2026;21:e0361188.
    PubMed         Abstract available
    
    
68. WANG YH, Aggarwal A, Davies EA
    Disparities in screening participation and stage at diagnosis for breast and bowel cancers among individuals with pre-existing mental health disorders: A population-based study.
    PLoS One. 2026;21:e0361617.
    PubMed         Abstract available
    
    
69. SILVA PVS, Silva LGSD, Cruz ACDC, Cavalcante Junior AG, et al
    Spatial distribution of the time between diagnosis and treatment of breast cancer among women in Brazil.
    PLoS One. 2026;21:e0361469.
    PubMed         Abstract available
    
    
70. DONG L, Liu C, Li L, Zhang X, et al
    Study on the association between the low-density lipoprotein to high-density lipoprotein ratio and clinicopathological characteristics of breast cancer: A retrospective analysis incorporating subgroup evaluations by age, body mass index, and menopausa
    PLoS One. 2026;21:e0361764.
    PubMed         Abstract available
    
    
71. DAS S, Patra S, Om S, Kundu S, et al
    Reported clinical breast examination activity in Bangladesh, 2019-2025: Temporal trends, geographic variation, positivity, and reporting completeness.
    PLoS One. 2026;21:e0361910.
    PubMed         Abstract available
    
    
72. BAIDOO D
    Multi-dimensional structure and subtype-specific heterogeneity of angiogenesis in breast cancer.
    PLoS One. 2026;21:e0348390.
    PubMed         Abstract available
    
    
73. CHIANG JK, Chiang PC, Koo M
    Electronic health record phenotype choice and real-world outcome estimates: A propensity score-matched comparison of three invasive breast cancer definitions in TriNetX.
    PLoS One. 2026;21:e0361883.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

74. 
    Correction for Ma et al., miR-182 targeting reprograms tumor-associated macrophages and limits breast cancer progression.
    Proc Natl Acad Sci U S A. 2026;123:e2635722123.
    PubMed        
    
    

    
    Radiol Artif Intell

75. CANTONE M, Zhang T, Marrocco C, Han L, et al
    DeepVEST: Deep Learning-based Vessel Segmentation and Erasure in Breast MRI for Improved Lesion Assessment.
    Radiol Artif Intell. 2026 Sep 9:e250630. doi: 10.1148/ryai.250630.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

76. LAMB LR, Mercaldo S, Destounis S, Bahl M, et al
    Screening Digital Breast Tomosynthesis Performance across Age Groups: Analysis of 302 700 Examinations.
    Radiol Imaging Cancer. 2026;8:e260066.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum